The use of prostaglandin analogs in the uveitic patient

Semin Ophthalmol. Jul-Sep 2011;26(4-5):285-9. doi: 10.3109/08820538.2011.588650.

Abstract

Glaucoma is a disease process characterized by progressive optic nerve damage and corresponding visual field loss. It may be further categorized into either primary open-angle glaucoma or secondary glaucoma. These secondary glaucomas include glaucomas associated with uveitis and inflammation. Prostaglandin analogs (PGA) have been used to help lower intraocular pressure (IOP) in these often difficult to manage eyes. However, controversy exists concerning their use in uveitic patients due to the theoretically higher risk of anterior uveitis, development of cystoid macular edema (CME), and reactivation of herpes simplex keratitis (HSK). There is little evidence that PGA disrupt the blood-aqueous barrier and only anecdotal evidence suggesting an increased risk of these rare findings. PGA may be used in uveitic glaucoma when other topical treatments have not lowered IOP to the patient's target range.

Publication types

  • Review

MeSH terms

  • Glaucoma, Open-Angle / drug therapy*
  • Glaucoma, Open-Angle / physiopathology
  • Humans
  • Intraocular Pressure / drug effects*
  • Prostaglandins, Synthetic / adverse effects
  • Prostaglandins, Synthetic / therapeutic use*
  • Uveitis / drug therapy*
  • Uveitis / physiopathology

Substances

  • Prostaglandins, Synthetic